Welcome to our dedicated page for Rallybio news (Ticker: RLYB), a resource for investors and traders seeking the latest updates and insights on Rallybio stock.
Rallybio Corp (RLYB) is a clinical-stage biotechnology company pioneering therapies for severe rare disorders through advanced modalities including antibodies and engineered proteins. This dedicated news hub provides investors and industry observers with essential updates on the company's scientific progress and operational developments.
Access timely reports on clinical trial milestones, regulatory submissions, and strategic collaborations. Our curated collection features verified press releases, financial disclosures, and analysis of RLYB's innovative pipeline targeting conditions like fetal/neonatal alloimmune thrombocytopenia.
Key updates include progress on therapeutic candidates, partnership announcements with research institutions, and financial performance summaries. The resource is particularly valuable for tracking Rallybio's unique approach combining validated biological mechanisms with novel treatment strategies.
Bookmark this page for streamlined access to Rallybio's latest advancements in rare disease research. Check regularly for authoritative reporting on clinical developments and corporate announcements from this innovative biopharma leader.
Rallybio Corporation (NASDAQ: RLYB) announced that an abstract for RLYB212, an anti-HPA-1a monoclonal antibody, was accepted for presentation at the 31st Congress of the International Society on Thrombosis and Haemostasis (ISTH) in Montreal from June 24-28. RLYB212 aims to prevent fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company is focused on developing therapies for severe rare diseases and has a robust pipeline, including RLYB116, a C5 complement inhibitor. Investors are reminded of the risks associated with clinical trials, potential funding challenges, and competition in the biotechnology sector.
Rallybio Corporation (Nasdaq: RLYB) announces significant progress in its clinical trials, particularly with RLYB212, an anti-HPA-1a monoclonal antibody, which achieved proof-of-concept by rapidly eliminating transfused platelets in HPA-1a negative subjects. The multiple dose cohort study for RLYB212 is now enrolling, with results expected in Q4 2023. The company also continues its Phase 1 study of RLYB116, targeting complement-related diseases. Financially, Rallybio reported a net loss of $66.7 million for 2022 but has $169 million in cash reserves, providing a runway into Q1 2025. Future data and collaborations are anticipated to drive further developments.
Rallybio Corporation has achieved clinical proof-of-concept for RLYB212 in a Phase 1b study aimed at preventing fetal and neonatal alloimmune thrombocytopenia (FNAIT). Results indicate that RLYB212 effectively eliminated transfused HPA-1a positive platelets in HPA-1a negative subjects within a week of administration. The study showcased a greater than 90% reduction in mean platelet elimination half-life compared to placebo. RLYB212 was well-tolerated with no serious adverse events. Rallybio plans to present the full results at a scientific conference in 2023 and is advancing a multi-dose cohort study in Europe.
Rallybio Corporation (Nasdaq: RLYB), a biotechnology company focused on therapies for rare diseases, will participate in two upcoming investor conferences. The Cowen 43rd Annual Healthcare Conference will take place on March 8, 2023 in Boston, featuring CEO Martin Mackay in a panel at 2:10 p.m. ET. Additionally, the Oppenheimer 33rd Annual Healthcare Conference is set for March 13, 2023, where COO Steve Uden will participate in a virtual fireside chat at 4:40 p.m. ET. Live webcasts of the presentations can be accessed on Rallybio’s website, with replays available for 30 days.
Rallybio Corporation (Nasdaq: RLYB) announced Jonathan I. Lieber as their new Chief Financial Officer, effective February 1, 2023. He succeeds Jeffrey Fryer, who will leave the company on February 15, 2023. With over 30 years in finance, Lieber previously served as CFO at Applied Genetic Technologies Corporation and has experience with several biopharma firms. His appointment is set during a crucial time for Rallybio as it advances its rare disease pipeline initiated in January 2018. CEO Martin Mackay expressed optimism about Lieber's leadership enhancing the company's strategic goals.
Rallybio Corporation (NASDAQ: RLYB) has made significant strides in its mission to develop therapeutics for rare diseases, as indicated in its recent update. Key milestones include the upcoming Phase 1b proof-of-concept data for RLYB212 expected in Q1 2023 and initial data from a Phase 1 study of RLYB116 anticipated in H2 2023. The company's cash runway has been extended into Q1 2025 following a follow-on offering in November 2022, yielding $55 million in gross proceeds, bolstering its financial position for future developments.
Rallybio Corporation (NASDAQ: RLYB) announced preclinical results showing that low doses of its HPA-1a-specific antibodies, RLYB211 and RLYB212, effectively clear HPA-1a-positive platelets and prevent alloimmunization in mothers, addressing the life-threatening Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT). The study, published in Blood, showed improved outcomes for treated mice, paving the way for potential preventative therapies, as no approved treatments for FNAIT exist. Rallybio anticipates discussing data from its Phase 1b study for RLYB212 in Q1 2023.
Rallybio (Nasdaq: RLYB) and AbCellera (Nasdaq: ABCL) have formed a strategic alliance to develop antibody-based therapeutics for rare diseases. This collaboration combines AbCellera's antibody discovery capabilities with Rallybio's expertise in clinical development. The companies aim to co-develop up to five therapeutic targets, enhancing Rallybio's pipeline and addressing unmet needs in rare metabolic diseases. Both CEOs emphasized the potential for transformative medicines through this partnership.
AbCellera (Nasdaq: ABCL) and Rallybio Corporation (Nasdaq: RLYB) have announced a strategic alliance aimed at developing novel antibody-based therapeutics for rare diseases. This multi-year collaboration combines AbCellera's advanced antibody discovery capabilities with Rallybio's expertise in rare disease clinical development. The partnership will focus on co-developing up to five therapeutic targets, starting with rare metabolic diseases, addressing significant unmet medical needs. Both companies aim to accelerate drug development and improve patient outcomes.
Rallybio Corporation (RLYB), a clinical-stage biotechnology company, announced its participation in a virtual fireside chat at the JMP Securities Hematology and Oncology Summit on December 7, 2022, at 1:40 p.m. ET. The event will be accessible via a live webcast on Rallybio's website, with an archived replay available for 30 days post-event. Founded in January 2018, Rallybio focuses on developing therapies for severe and rare diseases, with a strong portfolio in areas such as hematology and maternal fetal health. The company is headquartered in New Haven, Connecticut.
